NCT02169973View on ClinicalTrials.gov

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Healthy
Interventions
DRUG

JNJ-42165279

Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.

DRUG

11C-MK-3168

Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.

Trial Locations (1)

Unknown

Leuven

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02169973 - A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279 | Biotech Hunter | Biotech Hunter